GSK plc (GSK) |
|
35.13 -0.36 (-1.01%)
|
02-02 16:00 |
|
Open: |
35.43 |
Pre. Close: |
35.49 |
|
High:
|
35.61 |
Low:
|
34.865 |
|
Volume:
|
5,433,256 |
Market Cap:
|
71,915(M) |
|
|
|
Technical analysis |
as of: 2023-02-02 4:12:36 PM |
|
Overall:
|
  |
| Stoxline posted a SELL today, downgraded from higher rating. Downward movement to be expected. |
| Target: |
Six months: 41.8 One year: 48.82 |
| Support: |
Support1: 34.82 Support2: 34.22 |
| Resistance: |
Resistance1: 35.78 Resistance2: 41.8 |
| Pivot: |
35.27  |
| Moving Average: |
MA(5): 35.25 MA(20): 35.12
MA(100): 33.24 MA(250): 38.35 |
| MACD: |
MACD(12,26): 0 Signal(9): 0.1 |
| Stochastic oscillator: |
%K(14,3): 64 %D(3): 64 |
| RSI: |
RSI(14): 50 |
| 52-week: |
High: 46.97 Low: 28.46 |
| Average Vol(K): |
3-Month: 5,204 (K) 10-Days: 4,699 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ GSK ] has closed above bottom band by 32.9%. Bollinger Bands are 69.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 24 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
35.82 - 35.96 |
35.96 - 36.12 |
|
Low:
|
34.72 - 34.87 |
34.87 - 35.04 |
|
Close:
|
35.21 - 35.45 |
35.45 - 35.73 |
|
Company Description |
|
GSK plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, HIV, immuno-inflammation, oncology, anti-viral, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterial, and dermatology. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health categories. The company offers its consumer healthcare products in the form of nasal sprays, tablets, syrups, lozenges, gum and trans-dermal patches, caplets, infant syrup drops, liquid filled suspension, wipes, gels, effervescents, toothpastes, toothbrushes, mouthwashes, denture adhesives and cleansers, topical creams and non-medicated patches, lip balm, gummies, and soft chews. It has collaboration agreements with 23andMe; Lyell Immunopharma, Inc.; Novartis; Sanofi SA; Surface Oncology; Progentec Diagnostics, Inc.; Alector, Inc.; and CureVac AG., as well as strategic partnership with IDEAYA Biosciences, Inc. and Vir Biotechnology, Inc. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom. |
Headline News |
Thu, 02 Feb 2023
GSK plc (NYSE:GSK) Q4 2022 Earnings Call Transcript - Yahoo Finance
Thu, 02 Feb 2023
GSK rises Thursday, still underperforms market - MarketWatch
Thu, 02 Feb 2023
GSK Wins Approval for CKD Anemia Drug – with Conditions - BioSpace
Thu, 02 Feb 2023
Pharmalittle: GSK CEO warns U.K. pharma industry is at a 'tipping point'; Gavi tussles with vaccine makers over refunds - STAT
Thu, 02 Feb 2023
GSK's anemia drug Jesduvroq scores FDA green light - FiercePharma
Wed, 01 Feb 2023
U.S. FDA approves GSK's anemia drug for patients on dialysis - Reuters
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Outperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Outperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Outperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NYSE |
| Sector: Healthcare |
| Industry: Drug Manufacturers—General |
| Shares Out. |
2,520 (M) |
| Shares Float |
19,580 (M) |
|
% Held by Insiders
|
0 (%) |
|
% Held by Institutions
|
14.1 (%) |
|
Shares Short
|
15,870 (K) |
|
Shares Short P.Month
|
13,970 (K) |
Stock Financials |
|
EPS
|
2.88 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
2.89 |
|
EPS Est Next Year
|
2.84 |
|
Book Value (p.s.)
|
5.94 |
|
Profit Margin (%)
|
12.2 |
|
Operating Margin (%)
|
23.4 |
|
Return on Assets (ttm)
|
6.5 |
|
Return on Equity (ttm)
|
24.7 |
|
Qtrly Rev. Growth
|
18.7 |
|
Gross Profit (p.s.)
|
8.99 |
|
Sales Per Share
|
14.77 |
|
EBITDA (p.s.)
|
4.4 |
|
Qtrly Earnings Growth
|
-40.3 |
|
Operating Cash Flow
|
10,510 (M) |
|
Levered Free Cash Flow
|
-9,890 (M) |
Stock Valuations |
|
PE Ratio
|
12.19 |
|
PEG Ratio
|
0.9 |
|
Price to Book value
|
5.91 |
|
Price to Sales
|
2.37 |
|
Price to Cash Flow
|
8.42 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
2022-01-12 |
|
Ex-Dividend Date
|
2021-11-17 |
|
Your Ad Here
|
|
